Heartflow, Inc. Common Stock

Executive Summary

SELL, Medium conviction. Rated SELL, Medium conviction. HeartFlow delivered a very good Q2, raised FY26 guidance to $246M-$250M, and showed real margin progress, but the stock has run 54.4% in one month and now trades far above the quant engine's $39.62 value, with a business still generating negative EPS and targeting cash flow profitability only by mid-2028. The company looks better operationally than it did six months ago, but the stock looks better than the business.

Investment Thesis

HTFL is no longer a broken story. It is a good operating story in a stock that has become too expensive. The core issue at $42.08 is not whether the business is improving, it plainly is. The issue is whether the current price leaves enough upside after a 46.0% one-week move, a 54.4% one-month move, and a valuation of 59.7x sales on a company guiding to $246M-$250M of FY26 revenue and only targeting cash flow profitability by mid-2028. That setup is poor.

The positive case is real and should be respected. Q2 revenue reached $64.1M, U.S. revenue grew 51%, gross margin expanded to 83.3%, and Plaque revenue of $7.8M beat internal plan by about $4M. Management then raised full-year Plaque guidance to $29M-$31M and Plaque-activated accounts to about 1,250. Those are not cosmetic changes. They show that HeartFlow is finding product-market fit beyond the original FFRCT use case, and that AI is helping the cost side through autonomous processing and better workflow efficiency.

But the bear case rests on what has already been capitalized. A stock at nearly 60x sales cannot merely execute well. It has to keep surprising positively, quarter after quarter, while resolving reimbursement, patent, and evidence questions. Even management's own commentary notes that 2H guide implies steady growth off Q2 rather than a sharper step-up, and Plaque utilization remains well below the stated 60% applicability ceiling. That means the adoption curve is promising, but still early. Early adoption deserves upside. It does not deserve a near-perfect discount rate.

The case depends on three things. First, Plaque has to continue compounding fast enough to matter beyond a $29M-$31M FY26 contribution. Second, the margin path has to stay intact, with Q2's -24.5% EBITDA margin proving the new normal rather than a one-off. Third, the company must preserve credibility after a mixed earnings history that included three straight misses before the latest three beats. Conviction stays at Medium because the business momentum is genuine, but the stock now demands more than genuine momentum. It demands perfection.

Key Metrics

Financial Strength

The balance sheet is the least controversial part of the story. Leverage is low, liquidity is strong, and management cited $246.8M cash as sufficient to fund operations through profitability, which reduces financing risk despite ongoing losses. The more important question is operating leverage, and here the trend is encouraging: gross margin is already in the low-80s and EBITDA losses narrowed sharply in Q2. That said, this is still not a self-funding business, and a stock at 59.7x sales is valuing future cash generation years before it arrives.

Competitive Position

HeartFlow's moat rests on clinical datasets, physician workflow integration, and reimbursement-linked evidence, not on image analysis alone. That matters because AI tools can lower processing cost for many players, but they do not quickly recreate years of validation, installed accounts, or embedded cardiology workflows. The moat is real today, but only moderately durable unless Plaque, PCI Navigator, and upcoming RCT evidence deepen the clinical and reimbursement lead over the next 3-5 years.

Management & Guidance

Management did what investors needed to see in Q2: it raised revenue, Plaque, and margin guidance after a clean beat. CEO John Farquhar said, "We're now expected to deliver total revenue of $246 million to $250 million, representing 40% to 42% year-over-year growth." He also said, "We're also raising our full-year 2026 Plaque revenue outlook to a range of $29 million to $31 million. We're also raising our full-year guidance for Plaque-activated accounts to approximately 1,250." Credibility has improved because the last three quarters all beat EPS expectations by 47.6%, 14.7%, and 29.0%, but confidence should not be absolute given the three large misses before that, including the -630.0% miss in September 2025.

Segment Analysis

• Core HeartFlow platform plus Plaque (FY2025 revenue about $0.2B total, Plaque FY26 guide $29M-$31M): Plaque is the fastest-growing piece, with Q2 Plaque revenue $7.8M and activations ahead of plan
• United States (Geography not fully disclosed): U.S. revenue grew 51% and remains the main growth engine
• International (Geography not disclosed): No hard geographic split provided, which limits visibility into diversification outside the U.S.

Capital Allocation

Capital allocation is currently simple and mostly appropriate: no buybacks, no dividend, no visible M&A dependence, and minimal leverage with $0.0B debt and 0.09 debt/equity. The company is still in scale mode, so the key judgment is whether operating losses are buying durable commercial penetration and software-like gross margins. With $246.8M cash and a stated path to cash flow profitability by mid-2028, spending discipline looks acceptable, but investors are funding growth rather than receiving cash returns.

Positioning & Flows

Positioning is hot. The stock is near its high, short interest is 6.85M shares, or 10.33% of shares and 4.7 days-to-cover, and options gamma is positive with zero-gamma at $41.75, very close to spot, which can amplify upside squeezes after a beat. That helps explain the violent 1W and 1M move, but it also means incremental buyers are now paying after a squeeze-like setup rather than before it.

Bull Case

• Management raised FY26 revenue guidance to $246M-$250M, implying 40%-42% growth, after Q2 revenue reached $64.1M and U.S. revenue grew 51%
• Plaque is scaling faster than planned, with Q2 Plaque revenue of $7.8M, FY26 Plaque guidance raised to $29M-$31M, and Plaque-activated accounts lifted to about 1,250
• Gross margin reached 83.3% in Q2, up 770 bps YoY, with AI efficiencies and autonomous processing supporting a credible path toward higher long-run margins
• Balance sheet risk is low near term, with $246.8M cash, 0.09 debt/equity, and a 5.57 current ratio, which management says supports operations through profitability

Bear Case

• Valuation is extreme at 59.7x sales and 40x book, despite FY2025 revenue of only about $0.2B and EPS of -$0.32
• Even after the raise, 2H guidance implies only steady growth off Q2 rather than a sharper acceleration, which is a risk after the stock moved to within 2.1% of its high
• The profitability path is still long, with FY2025 operating margin at -36.4% and management only targeting cash flow profitability by mid-2028
• Execution credibility has improved in 2026, but the record is mixed, with three straight misses before the last three beats, including a -630.0% miss on 2025-09-19

Valuation & Price Target

Engine price target $39.62 (-5.8% vs current), Medium confidence.

• P/S Multiple: $10.01 (4% weight)
• Quality-adjusted: $45.45 (20% weight)

The quant baseline is HOLD with a $39.62 target, and the rating here is more cautious at SELL because the recent price action has pushed the stock to $42.08, or 5.8% above that target, while valuation remains disconnected from current earnings power at 59.7x sales and negative EPS. The business is executing better, with Q2 revenue of $64.1M, gross margin of 83.3%, and EBITDA margin improving to -24.5%, but the stock is trading as if the path to 2028 profitability and Plaque scaling are already de-risked. Sell-side consensus is still Strong Buy, but with only 2 firms it is low-signal context and does not offset the valuation stretch.

Risk Assessment

Risk score 47/100 (Moderate). The biggest risk to a bearish stance is that Plaque adoption and AI-led margin gains keep beating expectations, forcing the market to look through current losses toward a much larger revenue base than the present $246M-$250M FY26 guide.

The Bottom Line

HTFL rates SELL, Medium conviction. The company is executing, the product set is broadening, and AI is helping margins, but the stock is priced for a much cleaner and faster outcome than the business has yet delivered. At $42.08, investors are paying near-peak price for a company still losing money and targeting profitability in mid-2028. A move back toward the quant engine's $39.62 target would not make the business broken, it would make the valuation less demanding. The stance would change if either price corrected materially without a business deterioration, or if HeartFlow proves over the next few quarters that Plaque can scale fast enough to justify today's premium.